



Dr. Reddy's Laboratories Ltd.  
8-2-337, Road No. 3, Banjara Hills,  
Hyderabad - 500 034, Telangana,  
India.  
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900  
Fax : +91 40 4900 2999  
Email : mail@drreddys.com  
www.drreddys.com

January 23, 2017

Corporate Relationship Department  
BSE Limited  
Dalal Street, Fort  
Mumbai – 400 001  
Fax Nos.: 022-22723121 / 22723719 /  
22722037 / 22722039

National Stock Exchange of India Ltd.  
“Exchange Plaza”  
Bandra-Kurla Complex, Bandra (East),  
Mumbai – 400 051  
Fax Nos.: 022-26598120/ 26598237/  
26598238

**Scrip Code: 500124**

**Scrip Code: DRREDDY-EQ**


Dear Sirs,

**Sub: Press Release**

Please find enclosed a Press Release on “**Dr. Reddy's to release Q3 FY17 results on Feb 4, 2017 Earnings call slated for Feb 4, 6.30 PM IST / 8.00 AM EST.**”

This is for your information.

With regards,

  
Sandeep Poddar  
Company Secretary

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

**DR. REDDY'S LABORATORIES LTD.**

8-2-337, Road No. 3, Banjara Hills,  
Hyderabad - 500034. Telangana, India.

**CONTACT**

INVESTOR RELATIONS	MEDIA RELATIONS
SAUNAK SAVLA <a href="mailto:saunaks@drreddys.com">saunaks@drreddys.com</a> (Ph:+91-40-49002135)	CALVIN PRINTER <a href="mailto:calvinprinter@drreddys.com">calvinprinter@drreddys.com</a> (Ph: +91-40- 49002121)

**Dr. Reddy's to release Q3 FY17 results on Feb 4, 2017  
Earnings call slated for Feb 4, 6.30 PM IST / 8.00 AM EST**

Hyderabad, India, January 23, 2017

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Third Quarter and 9 months ended December 31, 2016 on Saturday, February 4, 2017 after the Board Meeting. The results will be available on the Company's website [www.drreddys.com](http://www.drreddys.com)

**Summary of Events**

Event	Date and Time	Medium
Release of financial results	Feb 4 <sup>th</sup> , after the Board Meeting	Email, Media, Company website, Businesswire
Earnings Call	Feb 4 <sup>th</sup> , 6.30 PM IST / 8:00 AM EST	Hosted by the Company (Details below)
Webcast of Earnings Call	Feb 4 <sup>th</sup> , 6.30 PM IST / 8.00 AM EST through Feb 8 <sup>th</sup>	URL available on Company's website, <a href="http://www.drreddys.com">www.drreddys.com</a>
Transcript of the Earnings call	Will be available on the Company's website	URL available on Company's website, <a href="http://www.drreddys.com">www.drreddys.com</a>
Press meet presentation	Will be available on the Company's website	URL available on Company's website, <a href="http://www.drreddys.com">www.drreddys.com</a>

**Earnings Call**

Following the release, the management of the Company will host an earnings call to discuss the Company's financial performance. *(Dial In and other details given below)*

**Audio Webcast**

The audio webcast of the earnings call will be available to all interested parties at [www.drreddys.com](http://www.drreddys.com). Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through Feb 8<sup>th</sup>, 2017. For play back dial in phone No: 022 3065 2322, 022 61813322 and ID: 375#.



Conference Dial-In Numbers	
Primary Number:	<b>+91 22 3960 0616</b>
<i>The numbers listed above are universally accessible from all networks and all countries.</i>	
Local Access Number:	<i>Accessible from all major carriers</i> <b>3940 3977</b> Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune <i>Accessible from all carriers.</i>
International Toll Free Number:	USA: <b>1 866 746 2133</b> UK: <b>0 808 101 1573</b> Singapore: <b>800 101 2045</b> Hong Kong: <b>800 964 448</b>

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.



**About Dr. Reddy's:** Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, Russia & CIS and India. For more information, log on to: [www.drreddys.com](http://www.drreddys.com)

**Disclaimer:** This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.